IQVIQVIA
Price
+37%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, undemanding price, growth steady, the market undecided.
IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
IQVIA (IQV) reported revenue of $4.15B in Q1 2026 (quarter ended Mar 31, 2026), up 8.4% from the same quarter a year earlier. That came with a gross margin of 33% and net income of $274M (6.6% of revenue). For the full year FY2025, revenue was $16.3B (+5.9% year on year) and net income $1.36B. Its largest segment in Jun 2026 was Research And Development Solutions at $1.14B, 56% of the disclosed total, ahead of Commercial Solutions at 44%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 23, 2026Notes Offering and Notes Indenture On September 23, 2026, IQVIA Inc. (the “Issuer”), a wholly owned subsidiary of IQVIA Holdings Inc., completed the issuance and sale of $2,000,000,000 in gross proceeds of 6.375% senior notes due 2034 (the “Notes”)Material agreement entered · Form 8-K
- Sep 9, 2026On September 9, 2026, IQVIA Holdings Inc. (the “Company”) issued a press release announcing that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 in gross proceeds through an offering of senior notes due 2034 (the “Notes Offering”) and intends to use the proceeds to redeem in …Other event · Form 8-K
- Jun 11, 2026Notes Offering and Notes Indenture On June 11, 2026, IQVIA Inc. (the “Issuer”), a wholly owned subsidiary of IQVIA Holdings Inc. (the “Company”), completed the issuance and sale of €950,000,000 in gross proceeds of 4.625% senior notes due 2033 (the “Notes”)Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $2.04BThe company’s own SEC segment disclosure.
- Research And Development Solutions$1.14B56%
- Commercial Solutions$895.0M44%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
The closest names by size in the same industry